In a recent study, the researchers suggested that targeting the circuits responsible for visual acuity may be necessary in achieving optimal recovery of visual function and could aid in the ...

Looking at innovative tools and their applications in different disease states can help to think creatively about ways to benefit patients in retina care.

A mutation-agnostic gene therapy approach offers new possibilities for patients with advanced retinal disease. Degenerative retinal disease progressively damages the photoreceptors responsible for ...

An Indonesian study of the characteristics of the retinal vasculature found that the retinal vessel tortuosity (VT) was significantly higher and the fractal dimension (FD) was significantly lower in ...

Two FDA-approved geographic atrophy treatments show significant patient dropout, with 45% discontinuation by 18 months, driven by baseline vision, CNV, and lack of immediate visual improvement. In a ...

International retina specialists converge to explore groundbreaking treatments, drug delivery systems, and surgical innovations at the Retina World Congress 2025. The Retina World Congress 2025, led ...

The pivotal phase 3 clinical trial is the first of 2 that will evaluate the use of DURAVYU for the treatment of wet age-related macular degeneration. EyePoint Pharmaceuticals recently announced the ...

Gore recently launched its silicone-free GORE IMPROJECT Plunger for 0.5-mL pre-filled syringes for the delivery of ophthalmic drugs. W. L. Gore and associates (Gore) announced the launch of its ...

Retina specialist Jay Chhablani, MD, discusses 3D choroidal vessel segmentation, uncovering critical insights into macular degeneration, diabetic retinopathy, and potential systemic disease ...

Sophie X. Deng, MD, PhD, FARVO, has stepped into the role as the new 2025-2026 Association for Research and Ophthalmology (ARVO) president. Deng has been part of ARVO for more than 20 years, is a ...

VG801 is a dual AAV gene therapy that leverages mRNA trans-splicing via the vgRNA REVeRT and vgAAV platforms to deliver the full-length ABCA4 gene for Stargardt disease and related retinal disorders.